Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Galluzzo

Showing results (41-50 of 111) with videos related to

Pageof 12
Sort By:
Italian Journal of Dermatology and Venereology|February 13, 2025
Treating psoriatic arthritis in the early phase: proposal for a shared dermatological and rheumatological therapeutic intervention with biologics and targets synthetic disease-modifying immunosuppressive drugsAndrea Picchianti Diamanti, Marco Galluzzo, Annunziata Dattola, et al.
International Journal of STD & AIDS|September 22, 2018
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO<sub>2</sub> ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trialMario Puviani, Marco Galluzzo, Marina Talamonti, et al.
Expert Opinion on Biological Therapy|March 27, 2023
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeksMarco Galluzzo, Lorenzo Marcelli, Laura Vellucci, et al.
Italian Journal of Dermatology and Venereology|May 21, 2019
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopySara Mazzilli, Alessandro Giunta, Marco Galluzzo, et al.
Immunology Letters|October 22, 2013
Genetic variations in IL6 and IL12B decreasing the risk for psoriasisAndreea Nicoleta Boca, Marina Talamonti, Marco Galluzzo, et al.
Journal of Clinical Medicine|January 28, 2026
Long-Term Impact of Guselkumab on Systemic Inflammation Indices in Moderate-to-Severe PsoriasisEdoardo Mortato, Lorenzo Marcelli, Agostino Panichelli, et al.
Skin Health and Disease|June 7, 2024
Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case reportMarco Galluzzo, Lorenzo Tofani, Sara Spelta, et al.
Vaccines|November 24, 2022
Allelic Variants of HLA-C Upstream Region, <i>PSORS1C3</i>, <i>MICA</i>, <i>TNFA</i> and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with PsoriasisMartina Morelli, Marco Galluzzo, Claudia Scarponi, et al.
The Journal of Dermatology|April 16, 2025
Effects of Guselkumab on the FIB-4 Index in Psoriasis Patients (EGIPT): A Three-Year StudyEdoardo Mortato, Lorenzo Marcelli, Lorenzo Tofani, et al.
Journal of Clinical Medicine|April 13, 2024
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective StudyClaudia Paganini, Virginia Maffei, Laura Vellucci, et al.
Pageof 12

Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
Italian Journal of Dermatology and Venereology|February 13, 2025
Treating psoriatic arthritis in the early phase: proposal for a shared dermatological and rheumatological therapeutic intervention with biologics and targets synthetic disease-modifying immunosuppressive drugsAndrea Picchianti Diamanti, Marco Galluzzo, Annunziata Dattola, et al.
International Journal of STD & AIDS|September 22, 2018
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO<sub>2</sub> ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trialMario Puviani, Marco Galluzzo, Marina Talamonti, et al.
Expert Opinion on Biological Therapy|March 27, 2023
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeksMarco Galluzzo, Lorenzo Marcelli, Laura Vellucci, et al.
Italian Journal of Dermatology and Venereology|May 21, 2019
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopySara Mazzilli, Alessandro Giunta, Marco Galluzzo, et al.
Immunology Letters|October 22, 2013
Genetic variations in IL6 and IL12B decreasing the risk for psoriasisAndreea Nicoleta Boca, Marina Talamonti, Marco Galluzzo, et al.
Journal of Clinical Medicine|January 28, 2026
Long-Term Impact of Guselkumab on Systemic Inflammation Indices in Moderate-to-Severe PsoriasisEdoardo Mortato, Lorenzo Marcelli, Agostino Panichelli, et al.
Skin Health and Disease|June 7, 2024
Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case reportMarco Galluzzo, Lorenzo Tofani, Sara Spelta, et al.
Vaccines|November 24, 2022
Allelic Variants of HLA-C Upstream Region, <i>PSORS1C3</i>, <i>MICA</i>, <i>TNFA</i> and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with PsoriasisMartina Morelli, Marco Galluzzo, Claudia Scarponi, et al.
The Journal of Dermatology|April 16, 2025
Effects of Guselkumab on the FIB-4 Index in Psoriasis Patients (EGIPT): A Three-Year StudyEdoardo Mortato, Lorenzo Marcelli, Lorenzo Tofani, et al.
Journal of Clinical Medicine|April 13, 2024
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective StudyClaudia Paganini, Virginia Maffei, Laura Vellucci, et al.
Pageof 12